Generic Alkeran launches from Fresenius Kabi

Press enter to search
Close search
Open Menu

Generic Alkeran launches from Fresenius Kabi

Fresenius Kabi has introduced its generic Alkeran (melphalan hydrochloride for injection). The drug is indicated as a palliative treatment for patients with multiple myeloma for whom oral therapy is not appropriate.

Fresenius Kabi’s generic Alkeran is available as a two-vial kit with one single-dose vial of the drug and one vial of sterile diluent.

This is the third launch in recent weeks from the Lake Zurich, Ill.-based company, which earlier in April launched its generic Cubicin and an alternative to Aloxi.

Related Topics